Ubs Group Ag Lumos Pharma, Inc. Call Options Transaction History
Ubs Group Ag
- $452 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding LUMO
# of Institutions
33Shares Held
2.2MCall Options Held
0Put Options Held
0-
Private Advisor Group, LLC745KShares$3.22 Million0.02% of portfolio
-
Goldman Sachs Group Inc New York, NY362KShares$1.57 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA244KShares$1.06 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny214KShares$925,8140.0% of portfolio
-
Jefferies Group LLC New York, NY121KShares$522,4180.01% of portfolio
About LUMOS PHARMA, INC.
- Ticker LUMO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 8,396,070
- Market Cap $36.4M
- Description
- Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare en...